{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:44:13Z","timestamp":1781869453220,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ahj.2024.10.020","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T22:37:52Z","timestamp":1730759872000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-7215","authenticated-orcid":false,"given":"Satoshi","family":"Shoji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek D.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiha","family":"Sarwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.10.020_bib0001","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.10.020_bib0002","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.10.020_bib0003","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0004","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.10.020_bib0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0006","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.020_bib0007","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.10.020_bib0008","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ahj.2024.10.020_bib0009","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med [Internet]."},{"key":"10.1016\/j.ahj.2024.10.020_bib0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejhf.2853","article-title":"The win ratio method in heart failure trials: lessons learnt from EMPULSE","volume":"25","author":"Pocock","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.10.020_bib0011","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ehjacc\/zuac168","article-title":"Is the win ratio a win for cardiovascular trials? Generalized pairwise comparisons explained in a nutshell","volume":"12","author":"Kresoja","year":"2023","journal-title":"Eur Hear J Acute Cardiovasc Care"},{"key":"10.1016\/j.ahj.2024.10.020_bib0012","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacbts.2023.05.004","article-title":"Fallacies of using the win ratio in cardiovascular trials","volume":"8","author":"Ajufo","year":"2023","journal-title":"JACC Basic to Transl Sci [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0013","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/CIRCULATIONAHA.123.067786","article-title":"Win ratio: a seductive but potentially misleading method for evaluating evidence from clinical trials","volume":"149","author":"Butler","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.020_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.10.020_bib0015","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2023.02.001","article-title":"Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril\/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event","volume":"29","author":"MENTZ","year":"2023","journal-title":"J Card Fail [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0016","first-page":"895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.10.020_bib0017","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/sim.8967","article-title":"Win odds: An adaptation of the win ratio to include ties","volume":"40","author":"Brunner","year":"2021","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2024.10.020_bib0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pst.2251","article-title":"Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes","volume":"22","author":"Dong","year":"2023","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ahj.2024.10.020_bib0019","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/biom.12225","article-title":"An alternative approach to confidence interval estimation for the win ratio statistic","volume":"71","author":"Luo","year":"2015","journal-title":"Biometrics"},{"key":"10.1016\/j.ahj.2024.10.020_bib0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pst.1763","article-title":"A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components","volume":"15","author":"Dong","year":"2016","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ahj.2024.10.020_bib0021","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/10543406.2017.1397007","article-title":"The stratified win ratio","volume":"28","author":"Dong","year":"2018","journal-title":"J Biopharm Stat [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0022","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/pst.2293","article-title":"The stratified win statistics (win ratio, win odds, and net benefit)","volume":"22","author":"Dong","year":"2023","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ahj.2024.10.020_bib0023","article-title":"Use of win statistics to analyze outcomes in the DAPA-HF and DELIVER trials","volume":"2","author":"Kondo","year":"2023","journal-title":"NEJM Evid [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0024","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur J Heart Fail [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0025","first-page":"1","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"00","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.020_bib0026","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-024-02941-8","article-title":"A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials","volume":"30","author":"Kondo","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ahj.2024.10.020_bib0027","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1681\/ASN.0000000000000243","article-title":"Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol [Internet]"},{"key":"10.1016\/j.ahj.2024.10.020_bib0028","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: practical guidance based on previous experience","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.020_bib0029","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.10.020_bib30","doi-asserted-by":"crossref","unstructured":"S Shoji, SJ Greene, RJ Mentz. Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction, Heart Fail Rev, 2024, 29(6):1235\u20138. Available from: https:\/\/doi.org\/10.1007\/s10741-024-10432-8","DOI":"10.1007\/s10741-024-10432-8"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:04:03Z","timestamp":1739343843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324002825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"alternative-id":["S0002870324002825"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.10.020","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}